Yooyoung signs marketing agreement for novel combination of pravastatin and fenofibrate

Yooyoung Pharm says it has recently entered into an exclusive agreement with Belgium based 'LABORATOIRES SMB S.A. to locally market Pravafen, a combination of fenofibrate and pravastatin to treat mixed dyslipidemia.

Currently, Smb completed Phase III clinical trials for Pravafen and expects to use clinical data to get market authorization in the U.S and Europe.

"Based on the data from the...